Xyosted (Testosterone Enanthate) Patent Expiration, LOE Window & CMS Spending

Xyosted (Testosterone Enanthate) by Antares: Off-Patent Genericized (AB Competition), 11 AB generics, $41.2M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAntares
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$41.2M
2024 Medicare Part D Spend$28.9M
2024 Medicaid Spend$12.3M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 15.8% 2-yr change)